ClinicalTrials.gg
RecruitingNCT02743858Updated May 7, 2026

Lymphedema Surveillance Study

An observational study in Breast Cancer and Lymphedema, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

From the registry’s dates

  • Started Apr 2016; still recruiting 10 years 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,250
Ages
18 Years and older
Sex
Female
01

Study summary

This study is being done to find out how many women develop lymphedema after an axillary lymph node dissection. The investigators also want to look for reasons why some women get lymphedema and others don't. Specifically, the investigators want to do tests on the breast tissue that is removed at the time of surgery to see if they can identify inflammation in the breast tissue, which may increase a woman's risk for lymphedema. The investigators will also ask the patient to answer questions to see how much their quality of life is affected by lymphedema, and whether this study can help women by detecting lymphedema earlier.

02

Conditions studied

  • Breast Cancer
  • Lymphedema

Keywords

  • Lymphedema
  • Surveillance Program
  • Axillary Lymph Node Dissection
  • 16-220
03

In context

Breast Neoplasms

14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

This study's planned enrollment of 1,250 is above the median of 184 across 3,235 observational studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 327 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

MSK clinics

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female breast cancer patients over the age of 18
  • Patients consenting for unilateral axillary lymph node dissection (ALND) (prior history of sentinel lymph node allowed if \<6 months from consent)
  • Patients consenting for unilateral sentinel lymph node biopsy (SLNB) and possible ALND are eligible for initial entry into the study, but will become ineligible if ALND is not performed
  • Initially consented patients, treated with SLNB alone, who were originally considered ineligible to continue on study, will be approached for re-enrollment
  • Patients who self-identify as Black or White consenting for unilateral ALND or possible ALND will be approached for enrollment onto translational study (Cohort 3)

Exclusion criteria

Exclusion Criteria:

  • Male breast cancer patients
  • Patients consenting for bilateral axillary surgery
  • Patients with prior history of surgical excision of one or more axillary lymph nodes or SLNB, performed >6 months from date of consent
  • Patients with prior history of ALND
  • Patients with no breast surgery performed at MSK
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,250 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients who consent for ALND

    In patients treated with ALND, bilateral arm measurements will be obtained using the Perometer (Model 350 NT Perometer, Per-System) circumferential arm measurements with elastic tape taken at 4-cm intervals from the wrist to the shoulder \& the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements. Measurements will be performed at baseline (prior to surgery), post-operatively (after surgery) \& at scheduled timepoints of 6 months, 12 months, 18 months, \& 24 months after surgery for a total of 2 years. For a patient who is diagnosed with lymphedema at ≥ 13 months after surgery, surveillance will continue for an additional 12 months after \[lymphedema\] diagnosis, \& total surveillance time may exceed 2 years. Height \& weight will be obtained for each patient at baseline \& at each scheduled visit for the purpose of calculating BMI. All patients will complete the ULL-27 (upper limb lymphedema) quality-of-life questionnaire at baseline \& at each scheduled visit.

    Other: Bilateral arm measurements · Other: Body mass index (BMI) · Behavioral: Quality of Life Questionnaire

  • Patients treated with SLNB alone

    Study requirements which include arm measurements, height and weight and completion of a questionnaire at a single long-term follow-up timepoint, will be explained to the patient

    Other: Bilateral arm measurements · Other: Body mass index (BMI) · Behavioral: Quality of Life Questionnaire

  • ALND Translational Study Patients

    Patients will also be counseled about blood draws, which will include withdrawal of up to 20 mL of blood. Patients who are eligible and agree to participate will sign a consent form. Arm measurements, height and weight, blood draw (if applicable), and baseline questionnaire will be performed at first contact if possible, or at a follow-up scheduled visit prior to surgery.

    Other: Bilateral arm measurements · Other: Body mass index (BMI) · Behavioral: Quality of Life Questionnaire · Other: Blood draw

Interventions

  • OtherBilateral arm measurements

    Pts treated with ALND, bilateral arm measurements will be obtained using the Perometer (Model 350 NT Perometer, Per-System) circumferential arm measurements with elastic tape taken at 4-cm intervals from the wrist to the shoulder \& the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements. Measurements will be performed before surgery, post-operatively \& at timepoints of 6,12,18, \& 24 months after surgery for 2 years will be obtained using the Perometer (Model 350 NT Perometer, Per-System) for bioimpedance measurements. Pts who have not yet developed lymphedema by 2 years, an additional measurement at approx 3 years post-surgery will be performed. If pt is diag with lymphedema at the 3-year visit, she will be asked to continue on study for an additional year. Pts treated with SLNB alone, following re-consent, a long-term follow-up volumetric arm measurement will be obtained using the perometer \& circumferential arm measurements at a minimum of 2 years post-surgery.

  • OtherBody mass index (BMI)

    Height and weight will be obtained for each patient at baseline and at each scheduled visit for the purpose of calculating BMI. BMI will be correlated with the presence of inflammatory biomarkers in the tissue, as well as with lymphedema development.

  • BehavioralQuality of Life Questionnaire
  • OtherBlood draw

    Patients enrolled in the translational study (Cohort 3) will undergo blood draws for serum collection preoperatively and 12-24 months postoperatively to test for FGF2, IL4, IL10, TGFB, Leptin, IL6, and CRP. At both timepoints, up to 20 mL of blood will be collected.

06

What researchers measure

Primary outcomes

  1. number of incidences of lymphedema

    as defined by perometry using rigorous measurement protocols. Bilateral arm measurements will be obtained using the Perometer (Model 350 NT Perometer, Per-System) and the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements.

    Time frame: 2 year

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering Basking Ridge (Consent only)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Andrea Barrio, MD · Contact646-888-5117
  • Memorial Sloan Kettering Monmouth (Consent only)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Andrea Barrio, MD · Contact646-888-5117
  • Memorial Sloan Kettering Bergen (Consent only)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Andrea Barrio, MD · Contact646-888-5117
  • Memorial Sloan Kettering Commack (Consent only)
    Commack, New York 11725, United States
    Recruiting
    • Andrea Barrio, MD · Contact646-888-5117
  • Memorial Sloan Kettering Westchester (Consent only)
    Harrison, New York 10604, United States
    Recruiting
    • Andrea Barrio, MD · Contact646-888-5117
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Andrea Barrio, MD · Contact646-888-5117
    • Babak Mehrara, MD · Contact212-639-8639
    • Andrea Barrio, MD · Principal investigator
  • Memorial Sloan Kettering Nassau (Consent only)
    Uniondale, New York 11553, United States
    Recruiting
    • Andrea Barrio, MD · Contact646-888-5117
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02743858
Responsible party
Sponsor
First posted
Apr 19, 2016
Start date
Apr 2016
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
May 7, 2026

Study contacts

Andrea Barrio, MD
Contact
646-888-5117
Babak Mehrara, MD
Contact
212-639-8639
Andrea Barrio, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion